News

News 10.09.2026 ZURICH, Switzerland--(BUSINESS WIRE)--CDR-Life, Inc., a clinical-stage biotechnology company developing highly selective T cell engagers (TCEs) to treat cancer and autoimmune diseases, today announced its newest development candidate, CDR209, a novel T cell engager for the treatment of axial spondyloarthritis (axSpA) and potentially other HLA-B27 associated autoimmune diseases. "CDR209 represents an important...

News 02.09.2026 [Schlieren, Switzerland] — [2/09/2026] — NovaGo Therapeutics AG, a clinical-stage biotechnology company developing anti-Nogo-A biologics for diseases of the central nervous system, today announced the successful completion of a CHF 24 million (USD 30 million) Series B financing round. The round was led by Neurimmune and Pureos, with participation from...

News 28.08.2026 The jury for this year’s EY Entrepreneur Of The Year program has selected 13 individuals and their nine companies as finalists. The awards in three categories will be presented on October 23, 2026, at the Kongresshaus in Zurich. The audit and consulting firm EY has announced the finalists for the EY...

News 25.08.2026 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX, NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of medicines known as DARPin therapeutics (“Molecular Partners” or the “Company”), today reported corporate highlights and financial...

News 18.08.2026 Schlieren, Switzerland – August 17, 2026 The combined leadership role will strengthen operational excellence, digitalization, and technology development as InSphero continues to grow and scale its organization. InSphero AG today announced the promotion of Olivier Frey, PhD, to the combined role of Chief Operating Officer (COO) and Chief Technology Officer (CTO). Previously Vice...